It’s time to start looking after nurses to boost careBreast cancer drug exemestane may increase fracture risk
Women taking the anti-breast cancer drug exemestane (Aromasin) should have regular bone monitoring to assess fracture risk because the treatment speeds up loss of bone density, a study suggests.
Continue reading - simply register below
It only takes two minutes to do and you'll immediately have access to our news and opinion articles and you'll be able to sign up for our newsletters.
Already registered?
To check that you are registered please enter your email address below
Not registered?
Registration is free and takes just two minutes. After you register, you'll get access to our news and opinion stories and you'll be able to sign up to our newsletters.
Not activated?
If you are a registered subscriber you also need to activate your subscription in order to access your subscriber-only content and free learning units online.
